Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.07.2011 | Epidemiology

Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms

verfasst von: Julia Kravchenko, Igor Akushevich, Victoria L. Seewaldt, Amy P. Abernethy, H. Kim Lyerly

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The observed bimodal patterns of breast cancer incidence in the U.S. suggested that breast cancer may be viewed as more than one biological entity. We studied the factors potentially contributing to this phenomenon, specifically focusing on how disease heterogeneity could be linked to breast carcinogenesis mechanisms. Using empirical analyses and population-based biologically motivated modeling, age-specific patterns of incidence of ductal and lobular breast carcinomas from the SEER registry (1990–2003) were analyzed for heterogeneity and characteristics of carcinogenesis, stratified by race, stage, grade, and estrogen (ER)/progesterone (PR) receptor status. The heterogeneity of breast carcinoma age patterns decreased after stratification by grade, especially for grade I and III tumors. Stratification by ER/PR status further reduced the heterogeneity, especially for ER(+)/PR(−) and ER(−)/(−) tumors; however, the residual heterogeneity was still observed. The number of rate-limiting events of carcinogenesis and the latency of ductal and lobular carcinomas differed, decreasing from grade I to III, with poorly differentiated tumors associated with the least number of carcinogenesis stages and the shortest latency. Tumor grades play important role in bimodal incidence of breast carcinoma and have distinct mechanisms of carcinogenesis. Race and cancer subtype could play modifying role. ER/PR status contributes to the observed heterogeneity, but is subdominant to tumor grade. Further studies on sources of “remaining” heterogeneity of population with breast cancer (such as genetic/epigenetic characteristics) are necessary. The results of this study could suggest stratification rather than unification of breast cancer prevention strategies, risk assessment, and treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lilienfeld AM, Johnson EA (1955) The age distribution in female breast and genital cancers. Cancer 8:875–882PubMedCrossRef Lilienfeld AM, Johnson EA (1955) The age distribution in female breast and genital cancers. Cancer 8:875–882PubMedCrossRef
2.
Zurück zum Zitat Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558–1568PubMed Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558–1568PubMed
3.
Zurück zum Zitat Anderson WF, Matsuno R (2006) Breast cancer heterogeneity: a mixture of at least two main types? JNCI 98:948–951PubMed Anderson WF, Matsuno R (2006) Breast cancer heterogeneity: a mixture of at least two main types? JNCI 98:948–951PubMed
4.
Zurück zum Zitat Armitage P, Doll R (1957) A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 11:161–169PubMedCrossRef Armitage P, Doll R (1957) A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 11:161–169PubMedCrossRef
5.
Zurück zum Zitat Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25:3923–3929PubMedCrossRef Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25:3923–3929PubMedCrossRef
6.
Zurück zum Zitat Manton KG, Stallard E (1980) A two-disease model of female breast cancer: mortality in 1969 among white females in the United States. J NCI 64:9–16 Manton KG, Stallard E (1980) A two-disease model of female breast cancer: mortality in 1969 among white females in the United States. J NCI 64:9–16
7.
Zurück zum Zitat Manton KG, Akushevich I, Kravchenko J (2009). Cancer mortality and morbidity patterns in the U.S. population: an interdisciplinary approach. Springer, 455 pp Manton KG, Akushevich I, Kravchenko J (2009). Cancer mortality and morbidity patterns in the U.S. population: an interdisciplinary approach. Springer, 455 pp
9.
Zurück zum Zitat Anderson E (1950) Possible relationship between menopause and age at onset of breast cancer. Cancer 3:410–411PubMedCrossRef Anderson E (1950) Possible relationship between menopause and age at onset of breast cancer. Cancer 3:410–411PubMedCrossRef
10.
Zurück zum Zitat De Waard F (1979) Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst 63:549–552PubMed De Waard F (1979) Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst 63:549–552PubMed
11.
Zurück zum Zitat Anderson WF, Chatterjee N, Ershler WB (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27–36PubMedCrossRef Anderson WF, Chatterjee N, Ershler WB (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27–36PubMedCrossRef
12.
Zurück zum Zitat Anderson WF, Pfeiffer RM, Dores GM (2006) Comparison of age frequency distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899–1905PubMedCrossRef Anderson WF, Pfeiffer RM, Dores GM (2006) Comparison of age frequency distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899–1905PubMedCrossRef
13.
Zurück zum Zitat Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127–137PubMedCrossRef Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127–137PubMedCrossRef
14.
Zurück zum Zitat Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedCrossRef Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedCrossRef
15.
Zurück zum Zitat Pike MC, Krailo MD, Henderson BE et al (1983) “Hormonal” risk factors, “breast tissue age” and the age-incidence of breast cancer. Nature 303:767–770PubMedCrossRef Pike MC, Krailo MD, Henderson BE et al (1983) “Hormonal” risk factors, “breast tissue age” and the age-incidence of breast cancer. Nature 303:767–770PubMedCrossRef
16.
Zurück zum Zitat Colditz GA, Baer HJ, Tamimi RM (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York Colditz GA, Baer HJ, Tamimi RM (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York
17.
Zurück zum Zitat Nunney L (1999) Lineage selection and the evolution of multistage carcinogenesis. Proc Biol Sci 266:493–498PubMedCrossRef Nunney L (1999) Lineage selection and the evolution of multistage carcinogenesis. Proc Biol Sci 266:493–498PubMedCrossRef
18.
Zurück zum Zitat Parmigiani G, Berry D, Aquilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedCrossRef Parmigiani G, Berry D, Aquilar O (1998) Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedCrossRef
19.
Zurück zum Zitat Colditz GA, Rosner BA (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152:950–964PubMedCrossRef Colditz GA, Rosner BA (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152:950–964PubMedCrossRef
20.
Zurück zum Zitat Li CI, Anderson BO, Daling JR et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. J Am Med Assoc 289:1421–1424CrossRef Li CI, Anderson BO, Daling JR et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. J Am Med Assoc 289:1421–1424CrossRef
21.
Zurück zum Zitat Kruger S, Fahrenkrog T, Muller H (1999) Proliferative and apoptotic activity in lobular breast carcinoma. Int J Mol Med 4:171–174PubMed Kruger S, Fahrenkrog T, Muller H (1999) Proliferative and apoptotic activity in lobular breast carcinoma. Int J Mol Med 4:171–174PubMed
22.
Zurück zum Zitat Lacroix M, Toillon R-A, Leclercq G (2004) Stable “portrait” of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11:497–522PubMedCrossRef Lacroix M, Toillon R-A, Leclercq G (2004) Stable “portrait” of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11:497–522PubMedCrossRef
23.
Zurück zum Zitat Ferlicot S, Vincent-Salomon A, Medioni J (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 40:336–341PubMedCrossRef Ferlicot S, Vincent-Salomon A, Medioni J (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 40:336–341PubMedCrossRef
24.
Zurück zum Zitat Zhao H, Langerod A, Ji Y (2004) Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523–2536PubMedCrossRef Zhao H, Langerod A, Ji Y (2004) Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523–2536PubMedCrossRef
25.
Zurück zum Zitat Warnberg F, Nordgren H, Bergkvist L (2001) Tumor markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85:869–874PubMedCrossRef Warnberg F, Nordgren H, Bergkvist L (2001) Tumor markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85:869–874PubMedCrossRef
26.
Zurück zum Zitat Iglehart JD, Kerns BJ, Huper G (1995) Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34:253–263PubMedCrossRef Iglehart JD, Kerns BJ, Huper G (1995) Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34:253–263PubMedCrossRef
27.
Zurück zum Zitat Mommers EC, Leonhart AM, Falix F (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194:327–333PubMedCrossRef Mommers EC, Leonhart AM, Falix F (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194:327–333PubMedCrossRef
28.
Zurück zum Zitat Millis RR, Barnes DM, Lampejo OT (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef Millis RR, Barnes DM, Lampejo OT (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef
29.
Zurück zum Zitat Bijker N, Peterse JL, Duchateau L (2001) Histological type and marker expression of the primary tumor compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539–544PubMedCrossRef Bijker N, Peterse JL, Duchateau L (2001) Histological type and marker expression of the primary tumor compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539–544PubMedCrossRef
30.
Zurück zum Zitat Cserni G (2002) Tumor histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol 55:293–297PubMedCrossRef Cserni G (2002) Tumor histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol 55:293–297PubMedCrossRef
31.
Zurück zum Zitat Visscher D, Jimenez RE, Grayson M III (2000) Histopathologic analysis of chromosome aneuploidy in ductal carcinoma in situ. Hum Pathol 31:201–207PubMedCrossRef Visscher D, Jimenez RE, Grayson M III (2000) Histopathologic analysis of chromosome aneuploidy in ductal carcinoma in situ. Hum Pathol 31:201–207PubMedCrossRef
32.
Zurück zum Zitat Boeker W, Buerger H, Schmitz K (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195:415–421CrossRef Boeker W, Buerger H, Schmitz K (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195:415–421CrossRef
33.
Zurück zum Zitat Richard F, Pacyna-Gengelbach M, Schluns K (2000) Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89:305–310PubMedCrossRef Richard F, Pacyna-Gengelbach M, Schluns K (2000) Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89:305–310PubMedCrossRef
34.
Zurück zum Zitat Buerger H, Mommers EC, Littmann R (2000) Correlation of morphologic and cytogenetic parameters of genetic instability with chromosomal alterations in in situ carcinomas of the breast. Am J Clin Pathol 114:854–859PubMedCrossRef Buerger H, Mommers EC, Littmann R (2000) Correlation of morphologic and cytogenetic parameters of genetic instability with chromosomal alterations in in situ carcinomas of the breast. Am J Clin Pathol 114:854–859PubMedCrossRef
35.
Zurück zum Zitat Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histophatology 41:154–161 Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histophatology 41:154–161
36.
Zurück zum Zitat Roylance R, Gorman P, Harris W (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed Roylance R, Gorman P, Harris W (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed
37.
Zurück zum Zitat Ivshina A, George J, Senko O (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301PubMedCrossRef Ivshina A, George J, Senko O (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301PubMedCrossRef
38.
Zurück zum Zitat Sotiriou C, Wirapati P, Loi S (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMedCrossRef Sotiriou C, Wirapati P, Loi S (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMedCrossRef
39.
Zurück zum Zitat Zafrani B, Aubriot MH, Mouret E (2000) High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37:536–545PubMedCrossRef Zafrani B, Aubriot MH, Mouret E (2000) High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37:536–545PubMedCrossRef
40.
Zurück zum Zitat Ringberg A, Anagnostaki L, Anderson H (2001) Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514–1522PubMedCrossRef Ringberg A, Anagnostaki L, Anderson H (2001) Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514–1522PubMedCrossRef
41.
Zurück zum Zitat Finn RS, Dering J, Ginther C (2006) ER+ PR− breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. J Clin Oncol 24(18S):514 Finn RS, Dering J, Ginther C (2006) ER+ PR− breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. J Clin Oncol 24(18S):514
42.
Zurück zum Zitat Sorlie T, Tibshirani R, Parker J (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef Sorlie T, Tibshirani R, Parker J (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef
43.
Zurück zum Zitat Sorlie T, Wang Y, Xiao C (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analysis across three different platforms. BMC Genomics 7:127PubMedCrossRef Sorlie T, Wang Y, Xiao C (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analysis across three different platforms. BMC Genomics 7:127PubMedCrossRef
44.
Zurück zum Zitat Nguyen PL, Taghian AG, Katz MS (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378PubMedCrossRef Nguyen PL, Taghian AG, Katz MS (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378PubMedCrossRef
45.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
46.
Zurück zum Zitat Anders CK, Hsu DS, Broadwater G (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330PubMedCrossRef Anders CK, Hsu DS, Broadwater G (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330PubMedCrossRef
47.
Zurück zum Zitat Boecker W, Buerger H (2003) Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 36(1 Suppl):73–84PubMedCrossRef Boecker W, Buerger H (2003) Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 36(1 Suppl):73–84PubMedCrossRef
48.
Zurück zum Zitat Jones C, Nonni AV, Fulford L et al (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427PubMedCrossRef Jones C, Nonni AV, Fulford L et al (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427PubMedCrossRef
Metadaten
Titel
Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms
verfasst von
Julia Kravchenko
Igor Akushevich
Victoria L. Seewaldt
Amy P. Abernethy
H. Kim Lyerly
Publikationsdatum
01.07.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1347-z

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.